Initially, identified from cellular screening assays in 2007, GANT58 and GANT61 were demonstrated to be selective inhibitors of Hh-driven tumor growth because of their capacity to downregulate the transcriptional activity of Gli1 and Gli2 [458–461]. Here, GLI1 is linked to neoplasm.